Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles
Sign Up to like & getrecommendations! Published in 2020 at "Nano Today"
DOI: 10.1016/j.nantod.2020.100877
Abstract: Abstract The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Ola), which inhibits the repair of DNA single-strand breaks, has been approved recently by the Food and Drug Administration (FDA) of U.S. for treatment of advanced pancreatic… read more here.
Keywords: non brca; delivery; pancreatic cancer; jq1 ... See more keywords
Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Digestive Diseases"
DOI: 10.1111/1751-2980.13168
Abstract: Biliary tract cancers (BTCs) are aggressive tumors of the biliary system, which are often diagnosed at the advanced stage with a dismal prognosis. Among BTC patients, germline or somatic breast cancer‐related gene 1/2 (BRCA1/2) mutation… read more here.
Keywords: targeting brca; brca mutant; mutation; biliary tract ... See more keywords